Acalabrutinib: all 124 studies that test it
Page 2 of 2. Open to participants first (26), then studies with results posted, then the rest; newest registration first within each.
- Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial.Active, not recruitingNCT04604067Phase 2
- Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell LymphomaActive, not recruitingNCT04566887Phase 2
- A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for RabeprazoleCompletedNCT04564040Phase 1
- Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLLActive, not recruitingNCT04560322Phase 2
- Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)Active, not recruitingNCT04546620Phase 2
- A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)Active, not recruitingNCT04529772Phase 3
- Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic LeukemiaActive, not recruitingNCT04505254Phase 2
- Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLLStatus unknownNCT04502394Phase 1/2
- Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell LymphomaActive, not recruitingNCT04484012Phase 2
- Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System LymphomaActive, not recruitingNCT04462328Phase 1
- Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell LymphomaActive, not recruitingNCT04189757Phase 2
- Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Chronic Lymphocytic LeukemiaCompletedNCT04178798Phase 3
- A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell LymphomaActive, not recruitingNCT04115631Phase 2
- Acalabrutinib With Rituximab and Lenalidomide in Relapsed/Refractory B-cell Non-Hodgkin LymphomaCompletedNCT04094142Phase 2
- Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell LymphomaActive, not recruitingNCT03946878Phase 2
- A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's SyndromeActive, not recruitingNCT03899337Phase 2
- Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLLActive, not recruitingNCT03836261Phase 3
- Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients with Relapsed/refractory CLLCompletedNCT03787264Phase 2
- A Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL)CompletedNCT03571308Phase 1/2
- A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)Active, not recruitingNCT03328273Phase 1
- Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLLActive, not recruitingNCT03128879Phase 2
- A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCLActive, not recruitingNCT02972840Phase 3
- A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell LymphomaWithdrawnNCT02735876Phase 3
- Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic LeukemiaActive, not recruitingNCT02157324Phase 1